BioMarin Pharmaceuticals Inc (BMRN) is a publicly traded Healthcare sector company. As of May 20, 2026, BMRN trades at $51.91 with a market cap of $9.60B and a P/E ratio of 35.90. BMRN moved +0.76% today. Year to date, BMRN is -14.73%; over the trailing twelve months it is -16.24%. Its 52-week range spans $49.26 to $73.51. Analyst consensus is buy with an average price target of $89.31. Rallies surfaces BMRN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BMRN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BMRN recently traded at $51.91. Market cap is $9.60B. P/E ratio is 35.90. Revenue is $3.24B.
| Metric | Value |
|---|---|
| Price | $51.91 |
| Market Cap | $9.60B |
| P/E Ratio | 35.90 |
| EPS | $1.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $73.51 |
| 52-Week Low | $49.26 |
| Volume | 1.84M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.24B |
| Net Income | $268.74M |
| Gross Margin | 76.53% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.22B | $348.90M | $1.82 |
| 2024 | $2.85B | $426.86M | $2.25 |
| 2023 | $2.42B | $167.65M | $0.89 |
| 2022 | $2.10B | $141.56M | $0.76 |
18 analysts cover BMRN: 0 strong buy, 13 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $89.31.